Business Description
ISIN : US4489475073
Share Class Description:
IDT: Class BTotal Employee Number:
1,925Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 404.87 | |||||
Equity-to-Asset | 0.51 | |||||
Debt-to-EBITDA | 0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 6.56 | |||||
Beneish M-Score | -2.48 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -2 | |||||
3-Year EBITDA Growth Rate | 22.8 | |||||
3-Year EPS without NRI Growth Rate | 38.9 | |||||
3-Year FCF Growth Rate | 144.9 | |||||
3-Year Book Growth Rate | 22.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 9.27 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 74.31 | |||||
9-Day RSI | 67.59 | |||||
14-Day RSI | 65.75 | |||||
3-1 Month Momentum % | 20.23 | |||||
6-1 Month Momentum % | 27.67 | |||||
12-1 Month Momentum % | 1.72 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.92 | |||||
Quick Ratio | 1.92 | |||||
Cash Ratio | 0.82 | |||||
Days Sales Outstanding | 12.19 | |||||
Days Payable | 7.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.38 | |||||
Dividend Payout Ratio | 0.07 | |||||
Forward Dividend Yield % | 0.38 | |||||
5-Year Yield-on-Cost % | 0.38 | |||||
3-Year Average Share Buyback Ratio | 0.6 | |||||
Shareholder Yield % | 1.57 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 37.35 | |||||
Operating Margin % | 9.07 | |||||
Net Margin % | 6.41 | |||||
EBITDA Margin % | 10.75 | |||||
FCF Margin % | 4.34 | |||||
OCF Margin % | 6.09 | |||||
ROE % | 25.41 | |||||
ROA % | 12.55 | |||||
ROIC % | 28.37 | |||||
3-Year ROIIC % | -492.38 | |||||
ROC (Joel Greenblatt) % | 203.52 | |||||
ROCE % | 32.94 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 20.77 | |||||
Forward PE Ratio | 17.19 | |||||
PE Ratio without NRI | 17.88 | |||||
Shiller PE Ratio | 36.9 | |||||
Price-to-Owner-Earnings | 49.94 | |||||
PEG Ratio | 0.84 | |||||
PS Ratio | 1.34 | |||||
PB Ratio | 4.72 | |||||
Price-to-Tangible-Book | 5.16 | |||||
Price-to-Free-Cash-Flow | 30.77 | |||||
Price-to-Operating-Cash-Flow | 21.93 | |||||
EV-to-EBIT | 12.69 | |||||
EV-to-EBITDA | 10.72 | |||||
EV-to-Revenue | 1.15 | |||||
EV-to-FCF | 26.55 | |||||
Price-to-GF-Value | 1.35 | |||||
Price-to-Projected-FCF | 2.33 | |||||
Price-to-Median-PS-Value | 2.9 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.08 | |||||
Price-to-Graham-Number | 2.03 | |||||
| Price-to-Net-Current-Asset-Value | 6.69 | |||||
Earnings Yield (Greenblatt) % | 7.88 | |||||
FCF Yield % | 3.28 | |||||
Forward Rate of Return (Yacktman) % | 19.47 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:IDT
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
IDT Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,275.575 | ||
| EPS (TTM) ($) | 3.27 | ||
| Beta | 0.3701 | ||
| 3-Year Sharpe Ratio | 1.04 | ||
| 3-Year Sortino Ratio | 2.06 | ||
| Volatility % | 29.22 | ||
| 14-Day RSI | 65.75 | ||
| 14-Day ATR ($) | 1.788457 | ||
| 20-Day SMA ($) | 66.3535 | ||
| 12-1 Month Momentum % | 1.72 | ||
| 52-Week Range ($) | 45.72 - 69.15 | ||
| Shares Outstanding (Mil) | 24.87 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
IDT Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
IDT Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-11 11:00 | In 111 days | ||
| First quarter earnings conference call for 2027 | 2026-12-04 17:30 | In 104 days | ||
| First quarter earnings results for 2027 | 2026-12-04 16:30 | In 104 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-09-29 17:30 | In 38 days | ||
| Fourth quarter earnings results for 2026 | 2026-09-29 16:30 | In 38 days | ||
| Annual report for 2026 | 2026-09-29 | In 37 days | ||
| East Coast IDEAS Investor Conference | 2026-06-11 10:35 | 55.50 (-1.14%) | ||
| USD 0.070000 Cash Dividend | 2026-06-09 | 55.09 (-1.54%) | ||
| Third quarter earnings conference call for 2026 | 2026-06-03 17:30 | 55.41 (-0.97%) | ||
| Third quarter earnings results for 2026 | 2026-06-03 | 55.41 (-0.97%) |
IDT Corp Frequently Asked Questions
Guru Commentaries on NYSE:IDT
IDT Australia Ltd (IDT) announced another positive update with 1QFY25 revenue nearly doubling to $5.3 million. 1HFY25 revenue is expected to be $10.5 million, an 82% increase on the prior period. The company won $12.9 million of contracts in 2QFY25, mainly from returning customers and US based customers. This bodes well for continued revenue growth going forward along with improved profitability as customers transition from development work to higher margin manufacturing contracts. Importantly, the strongest growth is coming from the Advanced Therapies vertical, which typically attracts higher margins due to the need for more complex manufacturing processes.
IDT Australia Ltd (IDT) has been experiencing strong revenue growth since the management changes two years ago. Although profitability has not yet been achieved, the company is focused on improving profits and cash flow. The expectation is that continued revenue growth will outpace costs from investments in infrastructure and personnel, leading to improved financial performance in the second half of the financial year. Additionally, there is potential for higher margins as revenue shifts towards Advanced Therapies products.
